Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Nutritional SciencesFRA:RVKA Debt-to-Equity is 0.02 as of Sep. 2025, which is 33% below its 10-year median of 0.03. The stock has 3 warning signs investors should review. Among 703 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 92.46% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cambridge Nutritional Sciences's Debt-to-Equity or its related term are showing as below:
FRA:RVKA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.19
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Cambridge Nutritional Sciences was 0.19. The lowest was 0.01. And the median was 0.03.
FRA:RVKA's Debt-to-Equity is ranked better than 92.46% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:RVKA: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cambridge Nutritional Sciences Debt-to-Equity Related Terms
Cambridge Nutritional Sciences Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RVKA vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences (FRA:RVKA) has a Debt-to-Equity of 0.02 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cambridge Nutritional Sciences and its competitors. This is 33% below median its historical median of 0.03. Over the past decade, Cambridge Nutritional Sciences' Debt-to-Equity has ranged from 0.01 to 0.19. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #53 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is Cambridge Nutritional Sciences' Debt-to-Equity too high?
Cambridge Nutritional Sciences' current Debt-to-Equity of 0.02 is 33% below median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.19. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Cambridge Nutritional Sciences' value of 0.02 is 91.3% below this industry median. Based on the distribution chart, Cambridge Nutritional Sciences ranks #53 out of 703 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #53 out of 703 companies for Debt-to-Equity. This places Cambridge Nutritional Sciences in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Cambridge Nutritional Sciences' value of 0.02 is 91.3% below this benchmark. Historically, Cambridge Nutritional Sciences' own Debt-to-Equity has ranged from 0.01 to 0.19 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.23, Cambridge Nutritional Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambridge Nutritional Sciences's current Debt-to-Equity of 0.02 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current Debt-to-Equity is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 27.5% below its estimated fair value. The current Debt-to-Equity is 0.02, which is 33% below median its 10-year median of 0.03 and 91.3% below the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Debt-to-Equity is 0.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 
